keyword
MENU ▼
Read by QxMD icon Read
search

Dementia treatment

keyword
https://www.readbyqxmd.com/read/27935555/algoplus%C3%A2-scale-in-older-patients-with%C3%A2-dementia-a-reliable-real-world-pain%C3%A2-assessment-tool
#1
Fiammetta Monacelli, Alessio Signori, Laura Roffredo, Katiuscia Pace, Alessio Nencioni, Gisele Pickering, Macian Nicolas, Patrizio Odetti
Pain is still a neglected clinical issue in elderly people with dementia and/or communicative disorders, with an unacceptable higher rate of under diagnosis and under treatment. Cognitive deficit and emotional and psychological disturbances entangle pain symptoms, affecting patient self-report. So far, observational pain tools do not have fully adequate clinimetric properties and quality requirements for easy-to-use daily rating. Older patients with dementia represent a clinical challenge. The assessment of pain is important for improving clinical outcomes, such as functional status, frailty trajectories, comorbidity, and quality of life...
December 5, 2016: Journal of Alzheimer's Disease: JAD
https://www.readbyqxmd.com/read/27935239/effect-of-galantamine-on-attention-in-patients-with-alzheimer-s-disease-combined-with-cerebrovascular-disease
#2
Jeong Jin Park, Seong Hye Choi, SangYun Kim, Ae Young Lee, So Young Moon, Jun Hong Lee, Jae Cheol Kwon, Kyung Won Park, Bon D Ku, Hyun Jeong Han, Eun-Joo Kim, Yong S Shim
AIM: Patients with Alzheimer's disease (AD) and cerebrovascular disease (CVD) show greater attentional deficits compared with AD patients without CVD. The aim of the present study was to investigate the effect of galantamine on attention in AD patients with CVD. METHODS: In this open trial, 1512 patients with AD and CVD were recruited from 71 nationwide hospitals. The patients were given galantamine for 16 weeks. The primary outcome measure was the score on the Attention Questionnaire Scale (AQS), which measures the patients' attention in their daily lives...
December 9, 2016: Geriatrics & Gerontology International
https://www.readbyqxmd.com/read/27935151/patient-related-characteristics-associated-with-non-persistence-with-statin-therapy-in-elderly-patients-following-an-ischemic-stroke
#3
Martin Wawruch, Dusan Zatko, Gejza Wimmer, Jan Luha, Vasil Hricak, Jan Murin, Peter Kukumberg, Tomas Tesar, Adam Hloska, Rashmi Shah
PURPOSE: This study was aimed at evaluating the extent of non-persistence with statin therapy in elderly patients after an ischemic stroke and identifying patient-related characteristics that are risk factors for non-persistence. METHODS: The evaluable study cohort (n = 2748) was derived from the database of the largest health insurance provider in the Slovak Republic. Patients aged ≥65 years who were initiated on statin therapy following the diagnosis of an ischemic stroke during one full year (1 January 2010 to 31 December 2010) constituted this cohort...
December 9, 2016: Pharmacoepidemiology and Drug Safety
https://www.readbyqxmd.com/read/27933636/primary-headaches-in-an-elderly-population-seeking-medical-care-for-cognitive-decline
#4
Michele Feleppa, Silvia Fucci, Marcelo E Bigal
OBJECTIVES: To assess the prevalence of specific headache disorders in a population older than 65 years seeking consultation due to memory problems or cognitive impairment. METHODS: We verified the occurrence of headache symptoms and the impact of headaches on daily life. Headaches were classified as per the International Classification of Headache Disorders, 2nd edition (ICHD-2). All patients were screened with the Mini-Mental State Examination (MMSE), followed by the Selective Reminding Test and neuroimaging...
December 9, 2016: Headache
https://www.readbyqxmd.com/read/27932369/patient-safety-in-community-dementia-services-what-can-we-learn-from-the-experiences-of-caregivers-and-healthcare-professionals
#5
Sophie Behrman, Philip Wilkinson, Helen Lloyd, Charles Vincent
OBJECTIVES: this study aims to explore how patient safety in community dementia services is understood by caregivers, and healthcare professionals. METHODS: cross-sectional analysis of guided one-to-one interviews with 10 caregivers, and 10 healthcare professionals. RESULTS: caregivers and healthcare professionals identified a range of issues including medication errors, mis-communication between professionals, unclear service pathways and the effects of stress on caregivers' behaviour...
December 7, 2016: Age and Ageing
https://www.readbyqxmd.com/read/27931154/inhibition-of-ikk%C3%AE-by-celastrol-and-its-analogues-an-in-silico-and-in-vitro-approach
#6
Karpagam Veerappan, Sathishkumar Natarajan, Purushoth Ethiraj, Umashankar Vetrivel, Shila Samuel
CONTEXT: Alzheimer's disease (AD) is the most common form of dementia affecting the aged population and neuroinflammation is one of the most observed AD pathologies. NF-κB is the central regulator of inflammation and inhibitor κB kinase (IKK) is the converging point in NF-κB activation. Celastrol is a natural triterpene used as a treatment for inflammatory conditions. OBJECTIVE: This study determines the neuroprotective and inhibitory effect of celastrol on amyloid beta1-42 (Aβ1-42) induced cytotoxicity and IKKβ activity, respectively...
December 2017: Pharmaceutical Biology
https://www.readbyqxmd.com/read/27930593/usefulness-of-3-dimensional-stereotactic-surface-projection-fdg-pet-images-for-the-diagnosis-of-dementia
#7
Jahae Kim, Sang-Geon Cho, Minchul Song, Sae-Ryung Kang, Seong Young Kwon, Kang-Ho Choi, Seong-Min Choi, Byeong-Chae Kim, Ho-Chun Song
To compare diagnostic performance and confidence of a standard visual reading and combined 3-dimensional stereotactic surface projection (3D-SSP) results to discriminate between Alzheimer disease (AD)/mild cognitive impairment (MCI), dementia with Lewy bodies (DLB), and frontotemporal dementia (FTD).[F]fluorodeoxyglucose (FDG) PET brain images were obtained from 120 patients (64 AD/MCI, 38 DLB, and 18 FTD) who were clinically confirmed over 2 years follow-up. Three nuclear medicine physicians performed the diagnosis and rated diagnostic confidence twice; once by standard visual methods, and once by adding of 3D-SSP...
December 2016: Medicine (Baltimore)
https://www.readbyqxmd.com/read/27928694/effect-of-rutin-against-a-mitochondrial-toxin-3-nitropropionicacid-induced-biochemical-behavioral-and-histological-alterations-a-pilot-study-on-huntington-s-disease-model-in-rats
#8
Sarumani Natarajan Suganya, Thangarajan Sumathi
Dietary compounds like flavonoids may offer protection against neurodegeneration. Huntington's disease (HD) is a neurodegenerative disorder characterized by symptoms like chorea and dementia. 3-Nitropropionic acid (3-NP), a Succinate dehydrogenase (SDH) inhibitor produces behavioral, biochemical and histological changes in the striatum, mimics HD in animals and humans. The present study was designed to examine the protective activity of Rutin (RT), a primary flavonoid from citrus fruits, green tea on 3-NP induced experimental model of HD in rats...
December 8, 2016: Metabolic Brain Disease
https://www.readbyqxmd.com/read/27927959/vectored-intracerebral-immunization-with-the-anti-tau-monoclonal-antibody-phf1-markedly-reduces-tau-pathology-in-mutant-tau-transgenic-mice
#9
Wencheng Liu, Lingzhi Zhao, Brittany Blackman, Mayur Parmar, Man Ying Wong, Thomas Woo, Fangmin Yu, Dolan Sondhi, Stephen M Kaminsky, Ronald G Crystal, Steven M Paul
: Passive immunization with anti-tau monoclonal antibodies has been shown by several laboratories to reduce age-dependent tau pathology and neurodegeneration in mutant tau transgenic mice. These studies have used repeated high weekly doses of various tau antibodies administered systemically for several months and have reported reduced tau pathology of ∼40-50% in various brain regions. Here we show that direct intrahippocampal administration of the adeno-associated virus (AAV)-vectored anti-phospho-tau antibody PHF1 to P301S tau transgenic mice results in high and durable antibody expression, primarily in neurons...
December 7, 2016: Journal of Neuroscience: the Official Journal of the Society for Neuroscience
https://www.readbyqxmd.com/read/27926574/neural-activity-memory-and-dementias-serotonergic-markers
#10
Alfredo Meneses
Dysfunctional memory seems to be a key component of diverse dementias and other neuropsychiatric disorders; unfortunately, no effective treatment exists for this, probably because of the absence of neural biomarkers accompanying it. Diverse neurotransmission systems have been implicated in memory, including serotonin or 5-hydroxytryptamine (5-HT). There are multiple serotonergic pharmacological tools, well-characterized downstream signaling in mammals' species and neural markers providing new insights into memory functions and dysfunctions...
December 6, 2016: Behavioural Pharmacology
https://www.readbyqxmd.com/read/27926449/the-role-of-dopamine-in-the-pathophysiology-and-treatment-of-apathy
#11
T T-J Chong, M Husain
Disorders of diminished motivation, such as apathy, are common and prevalent across a wide range of medical conditions, including Parkinson's disease, Alzheimer's dementia, stroke, depression, and schizophrenia. Such disorders have a significant impact on morbidity and quality of life, yet their management lacks consensus and remains unsatisfactory. Here, we review laboratory and clinical evidence for the use of dopaminergic therapies in the treatment of apathy. Dopamine is a key neurotransmitter that regulates motivated decision making in humans and other species...
2016: Progress in Brain Research
https://www.readbyqxmd.com/read/27925607/therapeutic-touch-in-the-management-of-responsive-behavior-in-patients-with-dementia
#12
Ananthavalli Kumarappah, Helen Senderovich
Patients with dementia experience various behavioral symptoms in the course of their illnesses, which greatly affect their quality of life. Current treatment modalities are not always effective, and, thus, nonpharmacological approaches are the preferred first-line therapy for managing such symptoms. They generally address the basic needs of the person with dementia and provide humane care, often producing noticeable improvements in symptoms. Thus, such therapies should precede pharmacological interventions...
October 2016: Advances in Mind-body Medicine
https://www.readbyqxmd.com/read/27924187/evaluating-outcomes-in-patients-with-overactive-bladder-within-an-integrated-healthcare-delivery-system-using-a-treatment-patterns-analyzer
#13
Daniel B Ng, Melissa McCart, Christopher Klein, Chelsey Campbell, Robert Schoenhaus, Todd Berner
BACKGROUND: Overactive bladder (OAB) is a relatively common disease that has been linked to a variety of comorbidities, reductions in quality of life, and increased healthcare costs. Antimuscarinic agents are the standard of care among pharmacologic treatments for OAB, but these drugs are linked to high levels of anticholinergic burden, especially in the elderly. OBJECTIVE: To demonstrate how efficient data analysis can be used to identify gaps in care as a result of improvement strategies for OAB within an integrated healthcare delivery system setting...
September 2016: American Health & Drug Benefits
https://www.readbyqxmd.com/read/27922822/serum-protein-mediators-of-dementia-and-aging-proper
#14
Donald R Royall, Safa Al-Rubaye, Ram Bishnoi, Raymond F Palmer
The latent variable "δ" (for "dementia") appears to be uniquely responsible for the dementing aspects of cognitive impairment. Age, depressive symptoms, gender and the apolipoprotein E (APOE) ε4 allele are independently associated with δ. In this analysis, we explore serum proteins as potential mediators of age's specific association with δ in a large, ethnically diverse longitudinal cohort, the Texas Alzheimer's Research and Care Consortium (TARCC). 22 serum proteins were recognized as partial mediators of age's association with δ...
December 3, 2016: Aging
https://www.readbyqxmd.com/read/27917116/preliminary-evidence-of-apathetic-like-behavior-in-aged-vesicular-monoamine-transporter-2-deficient-mice
#15
Aron Baumann, Carlos G Moreira, Marta M Morawska, Sophie Masneuf, Christian R Baumann, Daniela Noain
Apathy is considered to be a core feature of Parkinson's disease (PD) and has been associated with a variety of states and symptoms of the disease, such as increased severity of motor symptoms, impaired cognition, executive dysfunction and dementia. Apart from the high prevalence of apathy in PD, which is estimated to be about 40%, the underlying pathophysiology remains poorly understood and current treatment approaches are unspecific and proved to be only partially effective. In animal models, apathy has been sub-optimally modeled, mostly by means of pharmacological and stress-induced methods, whereby concomitant depressive-like symptoms could not be ruled out...
2016: Frontiers in Human Neuroscience
https://www.readbyqxmd.com/read/27916702/chronic-kidney-disease-accelerates-cognitive-impairment-in-a-mouse-model-of-alzheimer-s-disease-through-angiotensin-ii
#16
Takashi Nakagawa, Yu Hasegawa, Ken Uekawa, Shokei Kim-Mitsuyama
Epidemiological studies suggest that chronic kidney disease (CKD) is a significant risk factor in the development of cognitive decline. However, the exact role of CKD in cognitive impairment or dementia is unclear. This work was performed to examine the potential impact of CKD on cognitive impairment in Alzheimer's disease (AD), focusing on angiotensin II. (1) CKD was induced in 5XFAD mice, an AD model mouse, and wild-type mice by feeding adenine-containing diet and the effect on cognitive function was compared between both strains...
December 1, 2016: Experimental Gerontology
https://www.readbyqxmd.com/read/27916019/promoting-early-dementia-diagnosis-a-video-designed-by-patients-for-patients
#17
Nina Baruch, Charlotte L Allan, Maureen Cundell, Samuel Clark, Brian Murray
Early diagnosis of dementia allows people to access effective treatment and make advance decisions while they still have capacity. We aimed to encourage people to attend memory clinic, in order to boost rates of diagnosis. We created a patient information video about Oxford Health NHS Foundation Trust Memory Clinics, to inform and empower those awaiting assessment and to promote early diagnosis. Fourteen people (patients, carers, and staff) were approached prior to developing the video to ascertain their views on the themes the video should cover...
December 5, 2016: International Psychogeriatrics
https://www.readbyqxmd.com/read/27915041/garlic-active-constituent-s-allyl-cysteine-protects-against-lipopolysaccharide-induced-cognitive-deficits-in-the-rat-possible-involved-mechanisms
#18
Mahboubeh Zarezadeh, Tourandokht Baluchnejadmojarad, Zahra Kiasalari, Siamak Afshin-Majd, Mehrdad Roghani
Neuroinflammation is known as a risk factor for cognitive deficit and dementia and its incidence increases with aging. S-allyl cysteine (SAC) is the active and main component of aged garlic extract with anti-inflammatory, neuroprotective, and nootropic potential. In this study, the protective effect of SAC against lipopolysaccharide (LPS)-induced cognitive deficit in the rat was investigated. For induction of learning and memory impairment and neuroinflammation, LPS was intraperitoneally injected at a dose of 167μg/kg for 7 days and SAC was administered p...
November 30, 2016: European Journal of Pharmacology
https://www.readbyqxmd.com/read/27914870/co-occurrence-and-predictors-of-three-commonly-occurring-behavioral-symptoms-in-dementia-agitation-aggression-and-rejection-of-care
#19
Scott Seung W Choi, Chakra Budhathoki, Laura N Gitlin
OBJECTIVE: To investigate co-occurrences of agitation, aggression, and rejection of care in community-dwelling families living with dementia. METHODS: Cross-sectional, secondary analysis from a randomized controlled trial testing a nonpharmacological intervention to reduce behavioral symptoms. We examined frequency of occurrence of presenting behaviors at baseline and their combination. Omnibus tests compared those exhibiting combinations of behaviors on contributory factors...
November 3, 2016: American Journal of Geriatric Psychiatry
https://www.readbyqxmd.com/read/27914038/serotonin-5-ht6-receptor-antagonists-in-alzheimer-s-disease-therapeutic-rationale-and-current-development-status
#20
Hilda Ferrero, Maite Solas, Paul T Francis, Maria J Ramirez
Alzheimer's disease (AD) is the most common cause of dementia in elderly people. Because of the lack of effective treatments for this illness, research focused on identifying compounds that restore cognition and functional impairments in patients with AD is a very active field. Since its discovery in 1993, the serotonin 5-HT6 receptor has received increasing attention, and a growing number of studies supported 5-HT6 receptor antagonism as a target for improving cognitive dysfunction in AD. This article reviews the rationale behind investigations into the targeting of 5-HT6 receptors as a symptomatic treatment for cognitive and/or behavioral symptoms of AD...
December 3, 2016: CNS Drugs
keyword
keyword
18210
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"